Jody A. Charnow

In a study, only androgen deprivation therapy with oral antiandrogens were associated with an increased risk for dementia and Alzheimer disease.

Metastatic prostate cancer (PCa) at diagnosis and recurrent metastatic PCa after initial treatment may be distinct biological entities with different survival trajectories, according to investigators.

In men with nonmetastatic castration-resistant prostate cancer, a PSA doubling time of less than 3 months vs 15 months or more increases the risk of metastasis, which in turn is associated with a large increase in healthcare utilization and costs.

Men in the highest tertile of high-sensitivity C-reactive protein level had a 30% increased risk for prostate cancer compared with those in the lowest tertile in adjusted analyses.